On September 21, INSILICO rose 5.35% in regular trading, trading at 64.6 HKD/share, with turnover of approximately HK$411 million. The rally was primarily driven by continued momentum from the company's Phase III clinical milestone and sustained insider buying by the chairman.

On the news front, INSILICO's lead AI-driven drug candidate Rentosertib completed first patient dosing in the Phase III GENESIS-IPF-3 trial at Peking Union Medical College Hospital on September 10, marking a landmark event as the world's first generative AI-driven novel drug to enter Phase III clinical trials. The 52-week study will enroll 320 subjects to evaluate Rentosertib's efficacy in idiopathic pulmonary fibrosis. Additionally, Chairman Aleksandrs Zavoronkovs purchased 113,500 shares on the open market between September 4 and 7 using personal funds, raising his stake to approximately 8.02%. Citi maintained a Buy rating on the stock with a target price of HK$85, designating INSILICO as its top pick in the AI drug discovery sub-sector.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)